Pathophysiology of multiple sclerosis

WikiDoc Resources for Pathophysiology of multiple sclerosis

Articles

Most recent articles on Pathophysiology of multiple sclerosis

Most cited articles on Pathophysiology of multiple sclerosis

Review articles on Pathophysiology of multiple sclerosis

Articles on Pathophysiology of multiple sclerosis in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Pathophysiology of multiple sclerosis

Images of Pathophysiology of multiple sclerosis

Photos of Pathophysiology of multiple sclerosis

Podcasts & MP3s on Pathophysiology of multiple sclerosis

Videos on Pathophysiology of multiple sclerosis

Evidence Based Medicine

Cochrane Collaboration on Pathophysiology of multiple sclerosis

Bandolier on Pathophysiology of multiple sclerosis

TRIP on Pathophysiology of multiple sclerosis

Clinical Trials

Ongoing Trials on Pathophysiology of multiple sclerosis at Clinical Trials.gov

Trial results on Pathophysiology of multiple sclerosis

Clinical Trials on Pathophysiology of multiple sclerosis at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Pathophysiology of multiple sclerosis

NICE Guidance on Pathophysiology of multiple sclerosis

NHS PRODIGY Guidance

FDA on Pathophysiology of multiple sclerosis

CDC on Pathophysiology of multiple sclerosis

Books

Books on Pathophysiology of multiple sclerosis

News

Pathophysiology of multiple sclerosis in the news

Be alerted to news on Pathophysiology of multiple sclerosis

News trends on Pathophysiology of multiple sclerosis

Commentary

Blogs on Pathophysiology of multiple sclerosis

Definitions

Definitions of Pathophysiology of multiple sclerosis

Patient Resources / Community

Patient resources on Pathophysiology of multiple sclerosis

Discussion groups on Pathophysiology of multiple sclerosis

Patient Handouts on Pathophysiology of multiple sclerosis

Directions to Hospitals Treating Pathophysiology of multiple sclerosis

Risk calculators and risk factors for Pathophysiology of multiple sclerosis

Healthcare Provider Resources

Symptoms of Pathophysiology of multiple sclerosis

Causes & Risk Factors for Pathophysiology of multiple sclerosis

Diagnostic studies for Pathophysiology of multiple sclerosis

Treatment of Pathophysiology of multiple sclerosis

Continuing Medical Education (CME)

CME Programs on Pathophysiology of multiple sclerosis

International

Pathophysiology of multiple sclerosis en Espanol

Pathophysiology of multiple sclerosis en Francais

Business

Pathophysiology of multiple sclerosis in the Marketplace

Patents on Pathophysiology of multiple sclerosis

Experimental / Informatics

List of terms related to Pathophysiology of multiple sclerosis

## Contents

* 1 Overview
* 2 Demyelination process
* 3 Demyelination patterns
* 3.1 Correlation with clinical courses
* 3.2 Correlation with MRI findings
* 3.3 Correlation with CSF findings
* 3.4 Response to therapy
* 4 Blood-brain barrier disruption
* 5 Neural and axonal damage
* 6 Spinal cord damage
* 7 Normal appearing brain tissues abnormalities
* 8 Research
* 9 History
* 10 See also
* 11 References
* 12 External links

## Overview[edit | edit source]

Multiple sclerosis is a disease in which the myelin (a fatty substance which covers the axons of nerve cells, important for proper nerve conduction) degenerates. This includes not only the usually known white matter demyelination, but also demyelination in the cortex and deep gray matter (GM) nuclei, as well as diffuse injury of the normal-appearing white matter.[1] GM atrophy is independent of the MS lesions and is associated with physical disability, fatigue, and cognitive impairment in MS[2]

## Demyelination process[edit | edit source]

According to the view of most researchers, a special subset of lymphocytes, called T cells, plays a key role in the development of MS. Under normal circumstances, these lymphocytes can distinguish between self and non-self. However, in a person with MS, these cells recognize healthy parts of the central nervous system as foreign and attack them as if they were an invading virus, triggering inflammatory processes and stimulating other immune cells and soluble factors like cytokines and antibodies.

Normally, there is a tight barrier between the blood and brain, called the blood-brain barrier, built up of endothelial cells lining the blood vessel walls. It should prevent the passage of antibodies through it, but in MS patients it does not work. A deficiency of uric acid has been implicated in this process. Uric acid added in physiological concentrations (i.e. achieving normal concentrations) is therapeutic in MS by preventing the breakdown of the blood brain barrier through inactivation of peroxynitrite.[3] The low level of uric acid found in MS victims is manifestedly causative rather than a consequence of tissue damage in the white matter lesions,[4] but not in the grey matter lesions.[5] Nevertheless, whether BBB dysfunction is the cause or the consequence of MS[6] is still disputed,because activated T-Cells can cross a healthy BBB when they express adhesion proteins [7]

According to a strictly immunological explanation of MS, the inflammatory processes triggered by the T cells create leaks in the blood-brain barrier. These leaks, in turn, cause a number of other damaging effects such as swelling, activation of macrophages, and more activation of cytokines and other destructive proteins such as matrix metalloproteinases. The final result is destruction of myelin, called demyelination.

Repair processes, called remyelination, also play an important role in MS. Remyelination is one of the reasons why, especially in early phases of the disease, symptoms tend to decrease or disappear temporarily. Nevertheless, nerve damage and irreversible loss of neurons occur early in MS. Proton magnetic resonance spectroscopy has shown that there is widespread neuronal loss even at the onset of MS, largely unrelated to inflammation.[8] Often, the brain is able to compensate for some of this damage, due to an ability called neuroplasticity. MS symptoms develop as the cumulative result of multiple lesions in the brain and spinal cord. This is why symptoms can vary greatly between different individuals, depending on where their lesions occur.

The oligodendrocytes that originally formed a myelin sheath cannot completely rebuild a destroyed myelin sheath. However, the central nervous system can recruit oligodendrocyte stem cells capable of proliferation and migration and differentiation into mature myelinating oligodendrocytes. The newly-formed myelin sheaths are thinner and often not as effective as the original ones. Repeated attacks lead to successively fewer effective remyelinations, until a scar-like plaque is built up around the damaged axons. Under laboratory conditions, stem cells are quite capable of proliferating and differentiating into remyelinating oligodendrocytes; it is therefore suspected that inflammatory conditions or axonal damage somehow inhibit stem cell proliferation and differentiation in affected areas[9]

## Demyelination patterns[edit | edit source]

Also known as Lassmann patterns[10], it is believed that they may correlate with differences in disease type and prognosis, and perhaps with different responses to treatment. This report suggests that there may be several types of MS with different immune-related causes, and that MS may be a family of several diseases.

The four identified patterns are [12]:

Pattern I
The scar presents T-cells and macrophages around blood vessels, with preservation of oligodendrocytes, but no signs of complement system activation.[11]
Pattern II
The scar presents T-cells and macrophages around blood vessels, with preservation of oligodendrocytes, as before, but also signs of complement system activation can be found.[12]
Pattern III
The scars are diffuse with inflammation, distal oligodendrogliopathy and microglial activation. There is also loss of myelin associated glycoprotein (MAG). The scars do not surround the blood vessels, and in fact, a rim of preserved myelin appears around the vessels. There is evidence of partial remyelinization and oligodendrocyte apoptosis.
Pattern IV
The scar presents sharp borders and oligodendrocyte degeneration, with a rim of normal appearing white matter. There is a lack of oligodendrocytes in the center of the scar. There is no complement activation or MAG loss.

The meaning of this fact is controversial. For some investigation teams it means that MS is a heterogeneous disease. Others maintain that the shape of the scars can change with time from one type to other and this could be a marker of the disease evolution.

### Correlation with clinical courses[edit | edit source]

No definitive relationship between these patterns and the clinical subtypes has been established by now, but some relations have been established. All the cases with PPMS (primary progressive) had pattern IV (oligodendrocyte degeneration) in the original study [13] and nobody with RRMS was found with this pattern. Balo concentric sclerosis lesions have been classified as pattern III (distal oligodendrogliopathy)[14]. Neuromyelitis optica was associated with pattern II (complement mediated demyelination), though they show a perivascular distribution, at difference from MS pattern II lesions[15].

### Correlation with MRI findings[edit | edit source]

The researchers are attempting this with magnetic resonance images to confirm their initial findings of different patterns of immune pathology and any evidence of possible disease “sub-types” of underlying pathologies. It is possible that such “sub-types” of MS may evolve differently over time and may respond differently to the same therapies. Ultimately investigators could identify which individuals would do best with which treatments.

It seems that Pulsed magnetization transfer imaging [PMID 16964602], diffusion Tensor MRI [PMID 16385020] and VCAM-1 enhanced MRI [13] could be able to show the pathological differences of these patterns.

### Correlation with CSF findings[edit | edit source]

Teams in Oxford and Germany, [14] [PMID 11673319] found correlation with CSF and progression in November 2001, and hypothesis have been made suggesting correlation between CSF findings and pathophysiological patterns[16]. In particular, B-cell to monocyte ratio looks promising. The anti-MOG antibody has been investigated but no utility as biomarker has been found [17], though this is disputed[18]. High levels of anti-nuclear antibodies are found normally in patients with MS. Antibobies against Neurofascin–186 could be involved in a subtype of MS [19]

### Response to therapy[edit | edit source]

The heterogeneous response to therapy can support the idea of hetherogeneous aetiology.

* Pattern II lesions patients are responsive to plasmapheresis, while others are not [15] [16][17].
* The subtype associated with macrophage activation, T cell infiltration and expression of inflammatory mediator molecules may be most likely responsive to immunomodulation with interferon-beta or glatiramer acetate.[PMID 12027786]
* People non-responsive to interferons are the most responsive to Copaxone [18][19]

## Blood-brain barrier disruption[edit | edit source]

A healthy blood-brain barrier shouldn't allow T-cells to enter the nervous system. Therefore BBB disruption has always been considered one of the early problems in the MS lesions. Recently it has been found that this happens even in non-enhancing lesions[20], and it has been found with iron oxide nanoparticles how macrophages produce the BBB disruption [21].

Abnormal tight junctions are present in both SPMS and PPMS. They appear in active white matter lesions and in NAGM in SPMS. They persist in inactive lesions, particularly in PPMS[22]

Apart from that, activated T-Cells can cross a healthy BBB when they express adhesion proteins [23].

Haemodinamics of the lesions has been messured and distortion has been found related to plaques distribution[24]. It was meassured through transcranial color-coded duplex sonography (TCCS).

## Neural and axonal damage[edit | edit source]

The axons of the neurons are damaged by the attacks or its byproducts. Currently no relationship has been established with the relapses or the attacks[25].

A relationship between neural damage and N-Acetyl-Aspartat concentration has been stablished, and this could lead to new methods for early MS diagnostic through magnetic resonance spectroscopy. [20]

## Spinal cord damage[edit | edit source]

Cervical spinal cord has been found to be affected by MS even without attacks, and damage correlates with disability[26].

## Normal appearing brain tissues abnormalities[edit | edit source]

Brain normal appearing white matter (NAWM) and grey matter (NAGM) show several abnormalities under MRI. This is currently an active field of research with no definitive results. It has been found that grey matter injury correlates with disability[27] and that there is high oxidative stress in lesions, even in the old ones. [28]

Cortical lesions also appear. They can be detected by double inversion recovery MRI. They have been observed specially in people with SPMS but they also appear in RRMS and clinically isolated syndrome. They are more frequent in men than in women[29]. These lesions can partly explain cognitive deficits.

## Research[edit | edit source]

Until recently, most of the data available came from post-mortem brain samples and animal models of the disease, such as the experimental autoimmune encephalomyelitis (EAE), an autoimmune disease that can be induced in rodents, and which is considered a possible animal model for multiple sclerosis.[30] However, since 1998 brain biopsies apart from the post-mortem samples were used, allowing researchers to identify the previous four different damage patterns in the scars of the brain.[31]

## History[edit | edit source]

The National MS society launched The Lesion Project to classify the different lesion patterns of MS.

Claudia F. Lucchinetti, MD from Mayo Clinic and collaborators from the U.S., Germany and Austria were chosen to conduct this study for their previous contributions in this area. They have amassed a large collection of tissue samples from people with MS through brain biopsies or autopsy. Claudia Lucchinetti was appointed director of this project. The group has reported promising findings on samples from 83 cases. They found four types of lesions, which differed in immune system activity. Within each person, all lesions were the same, but lesions differed from person to person.

The first article about pathophysiological heterogeneity was in 1996 [PMID 8864283] and has been confirmed later by several teams. Four different damage patterns have been identified by her team in the scars of the brain tissue. Understanding lesion patterns can provide information about differences in disease between individuals and enable doctors to make more accurate treatment decisions.

According to one of the researchers involved in the original research "Two patterns (I and II) showed close similarities to T-cell-mediated or T-cell plus antibody-mediated autoimmune encephalomyelitis, respectively. The other patterns (III and IV) were highly suggestive of a primary oligodendrocyte dystrophy, reminiscent of virus- or toxin-induced demyelination rather than autoimmunity."

Apart of this, recent achievements in related diseases, like neuromyelitis optica have shown that varieties previously suspected different from MS are in fact different diseases. In neuromyelitis optica, a team was able to identify a protein of the neurons, Aquaporin 4 as the target of the immune attack. This has been the first time that the attack mechanisme of a type of MS has been identified [32].

The investigators are now trying to identify the types of cells involved with tissue destruction, and examining clinical characteristics of the individuals from whom these tissues were taken.

The MS Lesion Project has just been renewed with a commitment of $1.2 million for three years. It is now part of the Promise 2010 campaign.

## See also[edit | edit source]

* Multiple sclerosis
* Multiple sclerosis borderline

## References[edit | edit source]

1. ↑ Lassmann H,Bruck W,Lucchinetti CF. The immunopathology of multiple sclerosis: an overview, Centre for Brain Research, Medical University of Vienna, Vienna, Austria, PMID 17388952
2. ↑ Pirko I, Lucchinetti CF, Sriram S, Bakshi R. Gray matter involvement in multiple sclerosis. Neurology. 2007 Feb 27;68(9):E9–10. PMID 17325269
3. ↑ Kean R, Spitsin S, Mikheeva T, Scott G, Hooper D (2000). "The peroxynitrite scavenger uric acid prevents inflammatory cell invasion into the central nervous system in experimental allergic encephalomyelitis through maintenance of blood-central nervous system barrier integrity". J. Immunol. 165 (11): 6511–8. PMID 11086092.CS1 maint: Multiple names: authors list (link) Full article[1]
4. ↑ Rentzos M, Nikolaou C, Anagnostouli M, Rombos A, Tsakanikas K, Economou M, Dimitrakopoulos A, Karouli M, Vassilopoulos D (2006). "Serum uric acid and multiple sclerosis". Clinical neurology and neurosurgery. 108 (6): 527–31. PMID 16202511.CS1 maint: Multiple names: authors list (link)
5. ↑ van Horssen,Brink,de Vries,van der Valk,Bo. The Blood-Brain Barrier in Cortical Multiple Sclerosis Lesions. PMID 17413323
6. ↑ Waubant E (2006). "Biomarkers indicative of blood-brain barrier disruption in multiple sclerosis". Dis. Markers. 22 (4): 235–44. PMID 17124345.
7. ↑ [multiple sclerosis at emedicine.com http://www.emedicine.com/neuro/topic228.htm#target1]
8. ↑ Filippi M, Bozzali M, Rovaris M, Gonen O, Kesavadas C, Ghezzi A, Martinelli V, Grossman R, Scotti G, Comi G, Falini A (2003). "Evidence for widespread axonal damage at the earliest clinical stage of multiple sclerosis". Brain. 126 (Pt 2): 433–7. PMID 12538409.CS1 maint: Multiple names: authors list (link)
9. ↑ Wolswijk, G. Chronic stage multiple sclerosis lesions contain a relatively quiescent population of oligodendrocyte precursor cells J Neurosci, 1998;18: 601-9. PMID 9425002
10. ↑ Devic’s disease: bridging the gap between laboratory and clinic, Ralf Gold, Christopher Linington, Brain, Vol. 125, No. 7, 1425-1427, July 2002 [2]
11. ↑ Holmes, Nick (15 November 2001). "Part 1B Pathology: Lecture 11 - The Complement System". Retrieved 2006-05-10.
12. ↑ Lucchinetti, Claudia (1999). "A quantitative analysis of oligodendrocytes in multiple sclerosis lesions - A study of 113 cases". Brain. 122 (12): 2279–2295. Retrieved 2006-05-10. Unknown parameter `|coauthors=` ignored (help); Unknown parameter `|month=` ignored (help)
13. ↑ Primary progressive multiple sclerosis [3]
14. ↑ (Article in Spanish) Estudio longitudinal mediante imagen de resonancia magnética (RM) del efecto de la azatioprina[4]
15. ↑ The Mystery of the Multiple Sclerosis Lesion, Frontiers Beyond the Decade of the Brain, Medscape [5]
16. ↑ Patterns of cerebrospinal fluid pathology correlate with disease progression in multiple sclerosis [6]
17. ↑ MOG antibodies in pathologically proven multiple sclerosis [7]
18. ↑ Recognition and degradation of myelin basic protein peptides by serum autoantibodies: novel biomarker for multiple sclerosis, Belogurov AA Jr, Kurkova IN, Friboulet A, Thomas D, Misikov VK, Zakharova MY, Suchkov SV, Kotov SV, Alehin AI, Avalle B, Souslova EA, Morse HC 3rd, Gabibov AG, Ponomarenko NA [8]
19. ↑ Early research into a treatment for progressive MS [9]
20. ↑ Soon D, Tozer DJ, Altmann DR, Tofts PS, Miller DH (2007). "Quantification of subtle blood-brain barrier disruption in non-enhancing lesions in multiple sclerosis: a study of disease and lesion subtypes". doi:10.1177/1352458507076970. PMID 17468443.CS1 maint: Multiple names: authors list (link)
21. ↑ Petry KG, Boiziau C, Dousset V, Brochet B (2007). "Magnetic resonance imaging of human brain macrophage infiltration". Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics. 4 (3): 434–42. doi:10.1016/j.nurt.2007.05.005. PMID 17599709.CS1 maint: Multiple names: authors list (link)
22. ↑ Leech S, Kirk J, Plumb J, McQuaid S (2007). "Persistent endothelial abnormalities and blood-brain barrier leak in primary and secondary progressive multiple sclerosis". Neuropathol. Appl. Neurobiol. 33 (1): 86–98. doi:10.1111/j.1365-2990.2006.00781.x. PMID 17239011.CS1 maint: Multiple names: authors list (link)
23. ↑ [multiple sclerosis at emedicine.com http://www.emedicine.com/neuro/topic228.htm#target1]
24. ↑ Intracranial Venous Haemodynamics in Multiple Sclerosis, Zamboni, Paolo; Menegatti, Erica; Bartolomei, Ilaria; Galeotti, Roberto; Malagoni, Anna M.; Tacconi, Giovanna; Salvi, Fabrizio [10]
25. ↑ Pascual AM, Martínez-Bisbal MC, Boscá I; et al. (2007). "Axonal loss is progressive and partly dissociated from lesion load in early multiple sclerosis". Neurology. 69 (1): 63–7. doi:10.1212/01.wnl.0000265054.08610.12. PMID 17606882.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
26. ↑ Agosta F, Pagani E, Caputo D, Filippi M (2007). "Associations between cervical cord gray matter damage and disability in patients with multiple sclerosis". Arch. Neurol. 64 (9): 1302–5. doi:10.1001/archneur.64.9.1302. PMID 17846269.CS1 maint: Multiple names: authors list (link)
27. ↑ Zhang Y, Zabad R, Wei X, Metz LM, Hill MD, Mitchell JR (2007). "Deep grey matter 'black T2' on 3 tesla magnetic resonance imaging correlates with disability in multiple sclerosis". doi:10.1177/1352458507076411. PMID 17468444.CS1 maint: Multiple names: authors list (link)
28. ↑ Holley JE, Newcombe J, Winyard PG, Gutowski NJ (2007). "Peroxiredoxin V in multiple sclerosis lesions: predominant expression by astrocytes". doi:10.1177/1352458507078064. PMID 17623739.CS1 maint: Multiple names: authors list (link)
29. ↑ Calabrese M, De Stefano N, Atzori M; et al. (2007). "Detection of cortical inflammatory lesions by double inversion recovery magnetic resonance imaging in patients with multiple sclerosis". Arch. Neurol. 64 (10): 1416–22. doi:10.1001/archneur.64.10.1416. PMID 17923625.CS1 maint: Explicit use of et al. (link) CS1 maint: Multiple names: authors list (link)
30. ↑ "Experimental Autoimmune Encephalomyelitis". All About Multiple Sclerosis. 08/13/2003. Retrieved 2006-05-10. Check date values in: `|year=` (help)
31. ↑ Lucchinetti, C. Bruck, W. Parisi, J. Scherhauer, B. Rodriguez, M. Lassmann, H.Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination Ann Neurol, 2000; 47(6):707-17. PMID 10852536
32. ↑ The IgG autoantibody links to the aquaporin 4 channel [11]

## External links[edit | edit source]

* The lesion project page
* Multiple sclerosis news
* MS News at Accelerated Cure Project

Multiple sclerosis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Multiple sclerosis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography or Ultrasound

CT Scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Alternative Therapies

Primary Prevention

Secondary Prevention

Tertiary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Pathophysiology of multiple sclerosis On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Pathophysiology of multiple sclerosis

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Pathophysiology of multiple sclerosis

CDC on Pathophysiology of multiple sclerosis

Pathophysiology of multiple sclerosis in the news

Blogs on Pathophysiology of multiple sclerosis

Directions to Hospitals Treating Multiple sclerosis

Risk calculators and risk factors for Pathophysiology of multiple sclerosis

Template:WH Template:WikiDoc Sources